Global biosimilar companies face regulatory challenges in China
This article was originally published in SRA
Executive Summary
Chinese regulatory requirements are making it difficult for biosimilar companies to incorporate China into global development programs, and, according to senior Pfizer representative, despite efforts by the country to clarify its biosimilar regulatory process through recent guidance, developing a biosimilar for the Chinese market continues to pose challenges.